Copyright
©The Author(s) 2022.
World J Stem Cells. Jul 26, 2022; 14(7): 539-555
Published online Jul 26, 2022. doi: 10.4252/wjsc.v14.i7.539
Published online Jul 26, 2022. doi: 10.4252/wjsc.v14.i7.539
Characteristics | n | FOXO3 expression | P value | |
Low | High | |||
Age (yr) | ||||
> 50 | 50 | 30 (60.00) | 20 (40.00) | 0.633 |
≤ 50 | 40 | 22 (55.00) | 18 (45.00) | |
Gender | ||||
Male | 80 | 46 (57.50) | 34 (42.50) | 1.000 |
Female | 10 | 6 (60.00) | 4 (40.00) | |
AJCC stage | ||||
I | 52 | 25 (48.08) | 27 (51.92) | 0.029 |
II-III | 38 | 27 (71.05) | 11 (28.95) | |
HBsAg | ||||
Negative | 19 | 8 (42.11) | 11 (57.89) | 0.119 |
Positive | 71 | 44 (61.97) | 27 (38.03) | |
Recurrence | ||||
No | 41 | 19 (46.34) | 22 (53.76) | 0.032 |
Yes | 49 | 33 (67.35) | 16 (32.65) | |
AFP (μg/L) | ||||
> 400 | 33 | 19 (57.6) | 14 (42.4) | 0.976 |
≤ 400 | 57 | 33 (57.9) | 24 (42.1) | |
Total bilirubin (μmol/L) | ||||
>20 | 15 | 5 (33.33) | 10 (66.67) | 0.036 |
≤ 20 | 75 | 47 (62.67) | 28 (37.33) | |
ALT (U/L) | ||||
> 45 | 31 | 20 (64.52) | 11 (35.48) | 0.348 |
≤ 45 | 59 | 32 (54.24) | 27 (45.76) | |
GGT | ||||
> 40 | 59 | 37 (62.7) | 22 (37.3) | 0.191 |
≤ 40 | 31 | 15 (48.4) | 16 (51.6) | |
Edmondson-Steiner grade | ||||
I-II | 61 | 28 (45.90) | 33 (54.10) | 0.001 |
III-IV | 29 | 24 (82.76) | 5 (17.24) | |
Tumor number | ||||
Single | 79 | 45 (56.97) | 34 (45.03) | 0.675 |
Multiple | 11 | 7 (63.64) | 4 (36.36) | |
Tumor size (cm) | ||||
> 5 | 28 | 24 (85.71) | 4 (14.29) | 0.001 |
≤ 5 | 62 | 28 (45.16) | 34 (54.84) |
Characteristics | Overall survival | |||||
Univariate analysis | Multivariate analysis | |||||
HR | 95%CI | P value | HR | 95%CI | P value | |
FOXO3 expression | 0.311 | (0.134-0.721) | 0.006 | 0.504 | (0.164-1.553) | 0.233 |
Low vs high | ||||||
Age (yr) | 0.721 | (0.352-1.476) | 0.371 | |||
≤ 50 vs > 50 | ||||||
Gender | 0.520 | (0.124-2.176) | 0.371 | |||
Male vs female | ||||||
AJCC stage | 2.277 | (1.123-4.616) | 0.022 | 1.203 | (0.555-2.604) | 0.640 |
I vs II-III | ||||||
HBsAg | 0.667 | (0.257-1.736) | 0.407 | |||
Negative vs positive | ||||||
Recurrence | 87.223 | (4.860-1565.443) | 0.002 | |||
No vs yes | ||||||
AFP (ng/mL) | 0.888 | (0.434-1.818) | 0.746 | |||
≤ 400 vs > 400 | ||||||
Total bilirubin (μmol/L) | 1.113 | (0.428-2.893) | 0.826 | |||
≤ 20 vs > 20 | ||||||
ALT (U/L) | 1.046 | (0.504-2.171) | 0.903 | |||
≤ 45 vs > 45 | ||||||
GGT (U/L) | 0.386 | (0.159-0.937) | 0.035 | 0.594 | (0.233-1.516) | 0.276 |
≤ 40 vs > 40 | ||||||
Edmondson-Steiner grade | 3.664 | (1.791-7.497) | < 0.001 | 1.839 | (0.560-3.445) | 0.478 |
I-II vs III-IV | ||||||
Tumor number | 1.810 | (0.742-4.417) | 0.192 | |||
Singlevs vs multiple | ||||||
Tumor size (cm) | 0.504 | (0.250-1.018) | 0.056 | |||
≤ 5 vs > 5 |
- Citation: Chen Q, Yang SB, Zhang YW, Han SY, Jia L, Li B, Zhang Y, Zuo S. miR-3682-3p directly targets FOXO3 and stimulates tumor stemness in hepatocellular carcinoma via a positive feedback loop involving FOXO3/PI3K/AKT/c-Myc. World J Stem Cells 2022; 14(7): 539-555
- URL: https://www.wjgnet.com/1948-0210/full/v14/i7/539.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v14.i7.539